Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 16 AL 30

Targeted Delivery of Montelukast for the Treatment of Alzheimer's Disease

Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK.

CNS Neurol Disord Drug Targets. 2022;21(10):913-925. doi: 10.2174/1871527320666210902163756.

Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration

Durairajan SSK, Selvarasu K, Bera MR, Rajaram K, Iyaswamy A, Li M.

Curr Mol Pharmacol. 2022;15(2):361-379. doi: 10.2174/1874467214666210906125318.

Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations

Bukhari SNA.

Curr Drug Deliv. 2022;19(1):17-31. doi: 10.2174/1567201818666210910162750.

Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development

Gayathri S, Raghu CH, Fayaz SM.

CNS Neurol Disord Drug Targets. 2022;21(5):409-426. doi: 10.2174/1871527320666210920120612.

Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease

Sivaraman B, Raji V, Velmurugan BA, Natarajan R.

CNS Neurol Disord Drug Targets. 2022;21(5):427-449. doi: 10.2174/1871527320666210928160159.

Precision Psychiatry: Machine Learning as a Tool to Find New Pharmacological Targets

Rema J, Novais F, Telles-Correia D.

Curr Top Med Chem. 2022;22(15):1261-1269. doi: 10.2174/1568026621666211004095917.

Computer Aided Drug Design Methodologies with Natural Products in the Drug Research Against Alzheimer's Disease

de Sousa NF, Scotti L, de Moura ÉP, Dos Santos Maia M, Rodrigues GCS, de Medeiros HIR, Lopes SM, Scotti MT.

Curr Neuropharmacol. 2022;20(5):857-885. doi: 10.2174/1570159X19666211005145952.

A Review on the In Vitro Evaluation of the Anticholinesterase Activity Based on Ellman's Method

de Almeida RBM, de Almeida Luz RLS, Leite FHA, Botura MB.

Mini Rev Med Chem. 2022;22(13):1803-1813. doi: 10.2174/1389557521666211027104638.

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms

Garcia-Romeu A, Darcy S, Jackson H, White T, Rosenberg P.

Curr Top Behav Neurosci. 2022;56:287-317. doi: 10.1007/7854_2021_267.

Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration

Durai P, Beeraka NM, Ramachandrappa HVP, Krishnan P, Gudur P, Raghavendra NM, Ravanappa PKB.

Curr Neuropharmacol. 2022;20(5):893-915. doi: 10.2174/1570159X19666211109141330.

The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on Donepezil

Gulcan HO, Kosar M.

Curr Top Med Chem. 2022 Mar 4;22(5):395-407. doi: 10.2174/1568026621666211111153626.

Research Advances in the Treatment of Alzheimer's Disease with Polysaccharides of Danggui-Shaoyao-San

Fu X, Liu Q, Sun X, Chang H, Liu Y, Han J.

J Alzheimers Dis. 2022;85(1):7-19. doi: 10.3233/JAD-210656.

A Comprehensive Review on Medicinal Herbs and Novel Formulations for the Prevention of Alzheimer's Disease

Singh B, Singh H, Singh B, Kumar N, Rajput A, Sidhu D, Kaur A, Arora S, Kaur S.

Curr Drug Deliv. 2022;19(2):212-228. doi: 10.2174/1567201818666211015152733.

A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease

Kumar M, Bansal N.

Curr Drug Targets. 2022;23(5):486-512. doi: 10.2174/1389450122666211118125233.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias